Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Je-Jung Lee, MD PhD, Tan-Huy Chu, Manh-Cuong Vo, Hye-Sung Park, Thangaraj Jaya Lakshmi, Seo-Yeon Ahn, MD, Ga-Young Song, Sung-Hoon Jung, MD, Hyeoung-Joon Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1819.

https://doi.org/10.1182/blood-2019-127964

Published: 2019

Journal Articles

Enhancement of Antitumor Immunity Using Dendritic Cells Combined with Lenalidomide and Programmed Death Ligand-1 Blockade in Multiple Myeloma Mouse Model

Je-Jung Lee, MD PhD, Manh-Cuong Vo, Sung-Hoon Jung, MD, Tan-Huy Chu, Hyun-Ju Lee, Thangaraj Jaya Lakshmi, Hyeoung-Joon Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3194.

https://doi.org/10.1182/blood-2018-99-112359

Published: 2018

Journal Articles

Multimodality Targeting of Dendritic Cell Vaccination Combined with Immunomodulatory Drug and Immune Checkpoint Blockade Has Synergistically Induced a Marked Tumor Regression By Modulating Tumor Microenvironment in a Murine Myeloma Model

Manh-Cuong Vo, Hyun-Ju Lee, Sung-Hoon Jung, MD, Thangaraj Jaya Lakshmi, Hye-Sung Park, Tan-Huy Chu, Hyeoung-Joon Kim, Je-Jung Lee, MD PhD

Blood (2017) 130 (Supplement 1): 5453.

https://doi.org/10.1182/blood.V130.Suppl_1.5453.5453

Published: 2017

Journal Articles

Dendritic Cell Vaccination Combined with Pomalidomide and Dexamethasone Ameliorated Antitumor Immunity By Skewing Immuno-Suppressive Status Toward Immuno-Supportive Status in a Murine Myeloma Model

Sung-Hoon Jung, MD, Seoyun Yang, Hyun-Ju Lee, Manh-Cuong Vo, Thangaraj Jaya Lakshmi, Hye-Sung Park, Tan-Huy Chu, Hyeoung-Joon Kim, Je-Jung Lee, MD PhD

Blood (2017) 130 (Supplement 1): 5454.

https://doi.org/10.1182/blood.V130.Suppl_1.5454.5454

Published: 2017

Journal Articles

Cytoplasmic Transduction Peptide-Fused Recombinant Tumor-Associated Antigens Elicit Potent Myeloma-Specific Cytotoxic T Lymphocytes By Loading Onto Dendritic Cells: Implications of Feasible Tumor Antigens for Clinical Application Against Multiple Myeloma

Hyun-Ju Lee, Sung-Hoon Jung, MD, Manh-Cuong Vo, Thangaraj Jaya Lakshmi, Hye-Sung Park, Tan-Huy Chu, Hyeoung-Joon Kim, Je-Jung Lee, MD PhD

Blood (2017) 130 (Supplement 1): 5455.

https://doi.org/10.1182/blood.V130.Suppl_1.5455.5455

Published: 2017

NARROW

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Enhancement of Antitumor Immunity Using Dendritic Cells Combined with Lenalidomide and Programmed Death Ligand-1 Blockade in Multiple Myeloma Mouse Model

Multimodality Targeting of Dendritic Cell Vaccination Combined with Immunomodulatory Drug and Immune Checkpoint Blockade Has Synergistically Induced a Marked Tumor Regression By Modulating Tumor Microenvironment in a Murine Myeloma Model

Dendritic Cell Vaccination Combined with Pomalidomide and Dexamethasone Ameliorated Antitumor Immunity By Skewing Immuno-Suppressive Status Toward Immuno-Supportive Status in a Murine Myeloma Model

Cytoplasmic Transduction Peptide-Fused Recombinant Tumor-Associated Antigens Elicit Potent Myeloma-Specific Cytotoxic T Lymphocytes By Loading Onto Dendritic Cells: Implications of Feasible Tumor Antigens for Clinical Application Against Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Enhancement of Antitumor Immunity Using Dendritic Cells Combined with Lenalidomide and Programmed Death Ligand-1 Blockade in Multiple Myeloma Mouse Model

Multimodality Targeting of Dendritic Cell Vaccination Combined with Immunomodulatory Drug and Immune Checkpoint Blockade Has Synergistically Induced a Marked Tumor Regression By Modulating Tumor Microenvironment in a Murine Myeloma Model

Dendritic Cell Vaccination Combined with Pomalidomide and Dexamethasone Ameliorated Antitumor Immunity By Skewing Immuno-Suppressive Status Toward Immuno-Supportive Status in a Murine Myeloma Model

Cytoplasmic Transduction Peptide-Fused Recombinant Tumor-Associated Antigens Elicit Potent Myeloma-Specific Cytotoxic T Lymphocytes By Loading Onto Dendritic Cells: Implications of Feasible Tumor Antigens for Clinical Application Against Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only